TBPH Stock Recent News

DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society, taking place November 2-5, 2022, in Maui, Hawaii. The data include three consecutive platform presentations on Wednesday, November 2, 2022, starting at 11:15 AM Maui, HI (5:15 PM ET / 2:15 PM PT / 9:15 PM GMT): Biaggioni I, et al.

Theravance Biopharma Inc. TBPH, +0.20% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61% . The company will purchase GSK's entire holdings of about 9.6 million shares at $9.75 a share with the closing expected Tuesday.

DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be webcast: Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13 at 11:10 am ET (8:10 am PT/4:10 pm IST) H.C.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2022 Conference Call.

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva?

Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.